Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) announced that the Biologics License Application (BLA) for HLX14, a denosumab biosimilar independently developed by its subsidiary Henlius Biotech (HKG: 2696), has been accepted by China’s National Medical Products Administration (NMPA). The application covers all indications currently approved in China for its reference drug, Amgen’s Xgeva.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Application Type | BLA – accepted (11 Sep 2026) |
| Product | HLX14, denosumab biosimilar |
| Developer | Henlius (HKG: 2696), subsidiary of Fosun Pharma (SHA: 600196; HKG: 2196) |
| Reference Drug | Amgen’s Xgeva (denosumab) |
| Indications Applied For | All indications currently approved in China for Xgeva |
| Specifications | 60 mg/mL; 120 mg/1.7 mL |
| Related Filings | NMPA accepted applications for 60 mg (1.0 mL)/vial and 60 mg (1.0 mL)/pre‑filled syringe specifications in December 2025 |
Product Profile & Global Footprint
- Molecule: Denosumab – a RANK ligand (RANKL) inhibitor that reduces bone resorption; reference products are used in oncology and bone health settings such as prevention of skeletal‑related events in patients with bone metastases.
- Approved Markets: HLX14 has already been approved for marketing in the United States, the European Union, the United Kingdom, and Canada, covering all locally approved indications of its respective reference products.
- China Presentation Strategy: With the 120 mg/1.7 mL BLA now accepted alongside the 60 mg vial and pre‑filled syringe applications accepted in December 2025, Henlius is pursuing a multi‑specification filing strategy mirroring the reference product’s presentations.
- Development Status: Independently developed by Henlius as part of its broad biosimilar portfolio.
Market Impact & Outlook
- China Commercialization Path: BLA acceptance moves HLX14 into formal NMPA review, positioning Henlius to bring a full‑label denosumab biosimilar to one of the world’s largest bone metastasis patient populations.
- Global Track Record as Leverage: Existing approvals in the US, EU, UK and Canada provide a strong regulatory precedent and commercial foundation that may support review confidence and international supply scale.
- Portfolio Synergy: The addition strengthens the Fosun Pharma–Henlius biosimilar franchise in oncology supportive care, complementing Henlius’ established global biosimilar pipeline.
- Competitive Landscape: Denosumab biosimilar competition is intensifying across major markets; pricing, launch timing, and reimbursement access in China were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory review timelines, approval outcomes, and commercial expectations for HLX14 in China. BLA acceptance does not guarantee approval. Actual results may differ due to risks including review outcomes, market adoption, pricing and reimbursement dynamics, and competition.-Fineline Info & Tech
